Spectrum Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Henderson NV United States (2002)
Status: Acquired by Repligen Corporation (2017)

Organization Overview

First Clinical Trial
2002
NCT00004202
First Marketed Drug
2002
fluorouracil (efudex)
First NDA Approval
2008
levoleucovorin (fusilev)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Neos Tx | NeoTherapeutics | Spectrum Pharmaceuticals, Inc | SPECTRUM PHARMS